DermTech, Inc.: peers
DermTech, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
DermTech, Inc., Accelerate Diagnostics, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | DermTech, Inc.base DMTK · 🇺🇸 US Percentile in Healthcare Percentile in USA | IB Acquisition Corp. IBAC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Accelerate Diagnostics, Inc. AXDX · 🇺🇸 US Percentile in Healthcare Percentile in USA | DarioHealth Corp. DRIO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Precipio, Inc. PRPO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Star Equity Holdings, Inc. STRR · 🇺🇸 US Percentile in Healthcare Percentile in USA | Sera Prognostics, Inc. SERA · 🇺🇸 US Percentile in Healthcare Percentile in USA | Insight Molecular Diagnostics Inc. IMDX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $52 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one5th of 8 | $55 MSep 28, 2026 · Market data4th of 8 | $58 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $42 MOct 22, 2026 · Market data6th of 8 | $38 MOct 22, 2026 · Market data7th of 8 | $37 MOct 15, 2026 · Market data8th of 8 | $82 MOct 30, 2026 · Market data2nd of 8 | $98 MOct 27, 2026 · Market data1st of 8 | $53 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | $12 MFY2024 · SEC4th of 6 | $22 MFY2025 · SEC3rd of 6 | $53 MFY2025 · SEC2nd of 6 | $172 MFY2025 · SEC1st of 6 | $0 MFY2025 · SEC6th of 6 | $4 MFY2025 · SEC5th of 6 | $17 M6 ranked |
| Net income (Higher is better) | —— | $3 MFY2025 · SEC1st of 7 | $-50 MFY2024 · SEC6th of 7 | $-42 MFY2025 · SEC5th of 7 | $-0 MFY2025 · SEC2nd of 7 | $-6 MFY2025 · SEC3rd of 7 | $-32 MFY2025 · SEC4th of 7 | $-50 MFY2025 · SEC7th of 7 | $-32 M7 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | 2752019 · Profile2nd of 4 | 160March 11, 2026 · Profile3rd of 4 | —— | 1,200December 31, 2025 · Profile1st of 4 | 72December 31, 2025 · Profile4th of 4 | —— | 2184 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | -3.0%FY2024 · SEC4th of 520th22nd | -17.3%FY2025 · SEC5th of 511th7th | +28.0%FY2025 · SEC2nd of 575th85th | +22.9%FY2025 · SEC3rd of 572nd82nd | ———— | +116.0%FY2025 · SEC1st of 593rd97th | +22.9%5 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | -0.2%FY2024 · SEC3rd of 527th32nd | -6.8%FY2025 · SEC5th of 514th15th | +38.1%FY2025 · SEC2nd of 585th94th | -5.0%FY2025 · SEC4th of 517th18th | ———— | +61.7%FY2025 · SEC1st of 592nd97th | -0.2%5 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | -17.5%FY2025 · SEConly one with it23rd23rd | ———— | ———— | ———— | ———— | -17.5%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | 23.1%FY2024 · SEC4th of 512th24th | 56.6%FY2025 · SEC2nd of 548th70th | 20.0%FY2025 · SEC5th of 59th20th | 46.4%FY2025 · SEC3rd of 532nd60th | ———— | 56.6%FY2025 · SEC1st of 548th70th | 46.4%5 ranked |
| Operating margin (Higher is better) | ———— | ———— | -301.8%FY2024 · SEC4th of 411th4th | -163.9%FY2025 · SEC3rd of 417th7th | -2.2%FY2025 · SEC2nd of 455th36th | -2.1%FY2025 · SEC1st of 455th36th | ———— | ———— | -83.1%4 ranked |
| Net margin (Higher is better) | ———— | ———— | -427.7%FY2024 · SEC4th of 47th2nd | -186.5%FY2025 · SEC3rd of 416th7th | -0.7%FY2025 · SEC1st of 459th41st | -3.4%FY2025 · SEC2nd of 456th36th | ———— | ———— | -95.0%4 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | -211.1%FY2024 · SEC4th of 514th5th | -116.6%FY2025 · SEC3rd of 520th7th | 0.7%FY2025 · SEC1st of 554th37th | -5.2%FY2025 · SEC2nd of 544th25th | ———— | -624.6%FY2025 · SEC5th of 54th1st | -116.6%5 ranked |
| Return on equity (Higher is better) | ———— | ———— | ———— | -59.6%FY2025 · SEC4th of 438th16th | -2.7%FY2025 · SEC1st of 471st39th | -11.2%FY2025 · SEC2nd of 466th32nd | -51.8%FY2025 · SEC3rd of 442nd18th | ———— | -31.5%4 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | 16.1×price Sep 28, 2026 · Market dataonly one with it23rd41st | ———— | ———— | ———— | ———— | ———— | ———— | 16.1×— |
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | 1.9×price Oct 22, 2026 · Market data2nd of 432nd48th | 0.6×price Oct 22, 2026 · Market data3rd of 411th19th | 0.2×price Oct 15, 2026 · Market data4th of 42nd4th | ———— | 24.2×price Oct 27, 2026 · Market data1st of 485th95th | 1.3×4 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | 0.6×price Oct 22, 2026 · Market data3rd of 49th9th | 2.6×price Oct 22, 2026 · Market data1st of 444th57th | 0.6×price Oct 15, 2026 · Market data4th of 48th8th | 1.1×price Oct 30, 2026 · Market data2nd of 420th23rd | ———— | 0.8×4 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | -62.8%price Oct 22, 2026 · Market data5th of 515th6th | 0.9%price Oct 22, 2026 · Market data1st of 572nd41st | -24.2%price Oct 15, 2026 · Market data2nd of 530th13th | -32.2%price Oct 30, 2026 · Market data4th of 525th11th | -25.8%price Oct 27, 2026 · Market data3rd of 528th12th | -25.8%5 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | 0.5×FY2025 · SEC3rd of 351st40th | 0.0×FY2025 · SEC1st of 310th7th | 0.1×FY2025 · SEC2nd of 319th14th | ———— | ———— | 0.1×3 ranked |
| Net debt to EBITDA (Lower is better) | ———— | ———— | ———— | ———— | -64.3×FY2025 · SEConly one with it0th0th | ———— | ———— | ———— | -64.3×— |
| Piotroski F-score (Higher is better) | —— | —— | —— | 3 of 9FY2025 · SEC2nd of 3 | 7 of 9FY2025 · SEC1st of 3 | 1 of 9FY2025 · SEC3rd of 3 | —— | —— | 3.0 of 93 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 3 of 6FY2025 · Scorecard2nd of 7 | 2 of 13FY2024 · Scorecard6th of 7 | 5 of 21FY2025 · Scorecard5th of 7 | 12 of 22FY2025 · Scorecard1st of 7 | 8 of 24FY2025 · Scorecard3rd of 7 | 2 of 14FY2025 · Scorecard7th of 7 | 5 of 17FY2025 · Scorecard4th of 7 | 29% passed7 ranked |
| Valuation checks (Higher is better) | —— | 2 of 3FY2025 · Scorecard1st of 6 | —— | 2 of 5FY2025 · Scorecard2nd of 6 | 2 of 5FY2025 · Scorecard2nd of 6 | 2 of 5FY2025 · Scorecard2nd of 6 | 1 of 4FY2025 · Scorecard5th of 6 | 0 of 5FY2025 · Scorecard6th of 6 | 40% passed6 ranked |
| Growth checks (Higher is better) | —— | —— | 1 of 6FY2024 · Scorecard3rd of 6 | 0 of 6FY2025 · Scorecard5th of 6 | 5 of 6FY2025 · Scorecard1st of 6 | 1 of 6FY2025 · Scorecard3rd of 6 | 0 of 3FY2025 · Scorecard5th of 6 | 4 of 6FY2025 · Scorecard2nd of 6 | 17% passed6 ranked |
| Profitability checks (Higher is better) | —— | 1 of 1FY2025 · Scorecard1st of 7 | 1 of 4FY2024 · Scorecard3rd of 7 | 1 of 5FY2025 · Scorecard4th of 7 | 2 of 5FY2025 · Scorecard2nd of 7 | 1 of 5FY2025 · Scorecard4th of 7 | 0 of 3FY2025 · Scorecard6th of 7 | 0 of 2FY2025 · Scorecard6th of 7 | 20% passed7 ranked |
| Financial health checks (Higher is better) | —— | 0 of 2FY2025 · Scorecard6th of 7 | 0 of 2FY2024 · Scorecard6th of 7 | 2 of 4FY2025 · Scorecard3rd of 7 | 3 of 5FY2025 · Scorecard1st of 7 | 3 of 5FY2025 · Scorecard1st of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 33% passed7 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | 0 of 1FY2024 · Scorecard2nd of 6 | 0 of 1FY2025 · Scorecard2nd of 6 | 0 of 1FY2025 · Scorecard2nd of 6 | 1 of 3FY2025 · Scorecard1st of 6 | 0 of 1FY2025 · Scorecard2nd of 6 | 0 of 1FY2025 · Scorecard2nd of 6 | 0% passed6 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 0.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 6 | —— | 15.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 6 | 15.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6 | 25.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 6 | 49.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 6 | 56.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 6 | 20.3%6 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 32026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 6 | —— | 212026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6 | 202026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 6 | 242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 6 | 482026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 6 | 442026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 6 | 236 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | 0.0 pp2026-Q2 against 2026-Q1 · 13F4th of 5 | —— | +3.4 pp2026-Q2 against 2026-Q1 · 13F1st of 5 | +0.3 pp2026-Q2 against 2026-Q1 · 13F3rd of 5 | +0.8 pp2026-Q2 against 2026-Q1 · 13F2nd of 5 | —— | -2.5 pp2026-Q2 against 2026-Q1 · 13F5th of 5 | +0.3 pp5 ranked |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | ———— | ———— | ———— | ———— | ———— | 7.1%FY2025 · SEConly one with it85th80th | ———— | ———— | 7.1%— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = DermTech, Inc.: How market caps are worked out; IB Acquisition Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Accelerate Diagnostics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; DarioHealth Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Precipio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Star Equity Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Sera Prognostics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Insight Molecular Diagnostics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| DermTech, Inc. | — | — | — |
| IB Acquisition Corp. | — | — | — |
| Accelerate Diagnostics, Inc. | -301.8%FY2024 | 11th percentile in Healthcaremedian -7.7%, 674 companies | 4th percentile in USAmedian 3.5%, 2,594 companies |
| DarioHealth Corp. | -163.9%FY2025 | 17th percentile in Healthcaremedian -7.7%, 674 companies | 7th percentile in USAmedian 3.5%, 2,594 companies |
| Precipio, Inc. | -2.2%FY2025 | 55th percentile in Healthcaremedian -7.7%, 674 companies | 36th percentile in USAmedian 3.5%, 2,594 companies |
| Star Equity Holdings, Inc. | -2.1%FY2025 | 55th percentile in Healthcaremedian -7.7%, 674 companies | 36th percentile in USAmedian 3.5%, 2,594 companies |
| Sera Prognostics, Inc. | — | — | — |
| Insight Molecular Diagnostics Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | DermTech, Inc. | IB Acquisition Corp. | Accelerate Diagnostics, Inc. | DarioHealth Corp. | Precipio, Inc. | Star Equity Holdings, Inc. | Sera Prognostics, Inc. | Insight Molecular Diagnostics Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | $22 MSEC3rd | $53 MSEC2nd | $172 MSEC1st | $0 MSEC5th | $4 MSEC4th |
| 2024 | — | — | $12 MSEC4th | $27 MSEC3rd | $42 MSEC2nd | $140 MSEC1st | $0 MSEC6th | $2 MSEC5th |
| 2023 | — | — | $12 MSEC4th | $20 MSEC3rd | $30 MSEC2nd | $161 MSEC1st | $0 MSEC6th | $2 MSEC5th |
| 2022 | — | — | $13 MSEC4th | $28 MSEC2nd | $20 MSEC3rd | $201 MSEC1st | $0 MSEC6th | $1 MSEC5th |
| 2021 | — | — | $12 MSEC4th | $21 MSEC2nd | $18 MSEC3rd | $169 MSEC1st | $0 MSEC6th | $2 MSEC5th |
| 2020 | — | — | $11 MSEC3rd | $8 MSEC4th | $16 MSEC2nd | $101 MSEC1st | $0 MSEC6th | $1 MSEC5th |
| 2019 | — | — | $9 MSEC2nd | $8 MSEC4th | $8 MSEC3rd | $94 MSEC1st | — | — |
| 2018 | — | — | $6 MSEC3rd | $7 MSEC2nd | $5 MSEC4th | $67 MSEC1st | — | — |
| 2017 | — | — | $4 MSEC3rd | $5 MSEC2nd | $3 MSEC4th | $457 MSEC1st | — | — |
| 2016 | — | — | $0 MSEC4th | $3 MSEC2nd | $2 MSEC3rd | $423 MSEC1st | — | — |
| 2015 | — | — | $0 MSEC4th | $1 MSEC3rd | $2 MSEC2nd | $463 MSEC1st | — | — |
| 2014 | — | — | $0 MSEC3rd | $0 MSEC4th | $1 MSEC2nd | $581 MSEC1st | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of DermTech, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- IB Acquisition Corp.IBAC · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $55 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $55 M (Sep 28, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Accelerate Diagnostics, Inc.AXDX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $58 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $58 M (last known, Jan 5, 2024) · revenue $12 M (year to December 2024)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- DarioHealth Corp.DRIO · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $42 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $42 M (Oct 22, 2026) · revenue $22 M (year to December 2025)98 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Precipio, Inc.PRPO · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $38 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $38 M (Oct 22, 2026) · revenue $53 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Star Equity Holdings, Inc.STRR · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $37 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $37 M (Oct 15, 2026) · revenue $172 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Sera Prognostics, Inc.SERA · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $82 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $82 M (Oct 30, 2026) · revenue $0 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Insight Molecular Diagnostics Inc.IMDX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $98 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $98 M (Oct 27, 2026) · revenue $4 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- Anixa Biosciences, Inc.ANIX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $117 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $117 M (Oct 29, 2026)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- Aspira Women's Health Inc.AWH · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $46 M market cap against $52 M · Same country: USAMarket cap $46 M (last known, Jan 5, 2024)94 of 100 (industry or sector 50 + size 29 + country 15)+ Add
- Enzo Biochem, Inc.ENZ · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $72 M market cap against $52 M · Same country: USAMarket cap $72 M (last known, Jan 5, 2024) · revenue $76 M93 of 100 (industry or sector 50 + size 28 + country 15)+ Add
- MaxCyte, Inc.MXCT · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $156 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $156 M (Oct 27, 2026) · revenue $33 M (year to December 2025)93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)+ Add
- Neuronetics, Inc.STIM · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $162 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $162 M (Oct 23, 2026) · revenue $149 M (year to December 2025)93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.